Terms: = Leukemia AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Treatment
379 results:
1. Advancements and Challenges in the treatment of AML.
Abaza Y; McMahon C; Garcia JS
Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e438662. PubMed ID: 38662975
[TBL] [Abstract] [Full Text] [Related]
2. Preparation and Evaluation of Chitosan Coated PLGA Nanoparticles Encapsulating Ivosidenib with Enhanced Cytotoxicity Against Human Liver Cancer Cells.
Alsulays BB; Aodah AH; Ahmed MM; Anwer MK
Int J Nanomedicine; 2024; 19():3461-3473. PubMed ID: 38617799
[TBL] [Abstract] [Full Text] [Related]
3. Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
Fruchtman H; Avigan ZM; Waksal JA; Brennan N; Mascarenhas JO
Leukemia; 2024 May; 38(5):927-935. PubMed ID: 38600315
[TBL] [Abstract] [Full Text] [Related]
4. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
[TBL] [Abstract] [Full Text] [Related]
5. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Pratz KW; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Döhner H; Récher C; Fiedler W; Yamamoto K; Wang J; Yoon SS; Wolach O; Yeh SP; Leber B; Esteve J; Mayer J; Porkka K; Illés Á; Lemoli RM; Turgut M; Ku G; Miller C; Zhou Y; Zhang M; Chyla B; Potluri J; DiNardo CD
Am J Hematol; 2024 Apr; 99(4):615-624. PubMed ID: 38343151
[TBL] [Abstract] [Full Text] [Related]
6. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Abaza Y; Winer ES; Murthy GSG; Shallis RM; Matthews AH; Badar T; Geramita EM; Kota VK; Swaroop A; Doukas P; Bradshaw D; Helenowski IB; Liu Y; Zhang H; Im A; Litzow MR; Perl AE; Atallah E; Altman JK
Am J Hematol; 2024 Apr; 99(4):606-614. PubMed ID: 38342997
[TBL] [Abstract] [Full Text] [Related]
7. Altered Oxidative Phosphorylation Confers Vulnerability on idh1-Mutant leukemia Cells: Is This Therapeutically Tractable?
Steensma DP
Blood Cancer Discov; 2024 Mar; 5(2):83-85. PubMed ID: 38331418
[TBL] [Abstract] [Full Text] [Related]
8. Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance.
Mishra R; Zokaei Nikoo M; Veeraballi S; Singh A
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203655
[TBL] [Abstract] [Full Text] [Related]
9. Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia.
Cui J; Chen X; Li C; Yan Q; Yuan G
Hematology; 2024 Dec; 29(1):2293512. PubMed ID: 38095287
[TBL] [Abstract] [Full Text] [Related]
10. treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Sutter T; Schittenhelm M; Volken T; Lehmann T
Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
[TBL] [Abstract] [Full Text] [Related]
11. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and idh inhibitors.
Madero-Marroquin R; DuVall AS; Saygin C; Wang P; Gurbuxani S; Larson RA; Stock W; Patel AA
Br J Haematol; 2024 Apr; 204(4):1238-1242. PubMed ID: 38073116
[TBL] [Abstract] [Full Text] [Related]
12. [Efficacy and Survival of Venetoclax Based Regimen in the treatment of Acute Myeloid leukemia].
Kong FC; Qi L; Huang WF; Yu M; Zhou YL; Ji DX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1676-1683. PubMed ID: 38071045
[TBL] [Abstract] [Full Text] [Related]
13. The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy.
Venugopal S; Watts J
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):192-197. PubMed ID: 38066868
[TBL] [Abstract] [Full Text] [Related]
14. Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid leukemia: A Retrospective Study from a Single-Center.
Kong FC; Qi L; Zhou YL; Yu M; Huang WF; Li F
Curr Med Sci; 2023 Dec; 43(6):1151-1161. PubMed ID: 38057538
[TBL] [Abstract] [Full Text] [Related]
15. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid leukemia.
Blackmon AL; Hourigan CS
Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
[TBL] [Abstract] [Full Text] [Related]
16. A comparative safety review of targeted therapies for acute myeloid leukemia.
Dalgetty M; Leurinda C; Cortes J
Expert Opin Drug Saf; 2023; 22(12):1225-1236. PubMed ID: 38014918
[TBL] [Abstract] [Full Text] [Related]
17. FDA Approval Summary: Ivosidenib in Combination with Azacitidine for treatment of Patients with Newly Diagnosed Acute Myeloid leukemia with an idh1 Mutation.
Woods A; Norsworthy KJ; Wang X; Vallejo J; Chiu Yuen Chow E; Li RJ; Sun J; Charlab R; Jiang X; Pazdur R; Theoret MR; de Claro RA
Clin Cancer Res; 2024 Apr; 30(7):1226-1231. PubMed ID: 38010220
[TBL] [Abstract] [Full Text] [Related]
18. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
19. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory idh1-mutated acute myeloid leukemia.
Yue Z; Pan C; Wang S; N Tse A; Sheng Y
Eur J Clin Pharmacol; 2024 Jan; 80(1):105-113. PubMed ID: 37917187
[TBL] [Abstract] [Full Text] [Related]
20. Ivosidenib in acute myeloid leukemia.
Bruzzese A; Labanca C; Martino EA; Mendicino F; Lucia E; Olivito V; Neri A; Imovilli A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2023; 24(18):2093-2100. PubMed ID: 37874005
[TBL] [Abstract] [Full Text] [Related]
[Next]